The combination of carboplatin and pacli taxel is the standard of care for the treatment of ovarian cancer, yet rates of recurrence and death remain high. We performed a prospective randomized phase III study to examine whether sequential administration of topotecan can improve the efficacy of carboplatin and paclitaxel in fi rst-line treatment of advanced epithelial ovarian cancer. Methods: A total of 1308 patients with previously untreated ovarian cancer (International Federation of Gynecology and Obstetrics stages IIB -IV) were randomly assigned to receive six cycles of paclitaxel and carboplatin followed by either four cycles of topotecan (TC-Top; 658 patients) or surveillance (TC; 650 patients) on a 3-week per cycle schedule. The primary endpoint was overall survival, and secondary endpoints were progression-free survival, response rate, toxicity, and quality of life. Time-to-event data were analyzed using the Kaplan -Meier method, and a stratifi ed log-rank test was used to compare distributions between treatment groups. Hazard ratios (HRs) with 95% confi dence intervals (CIs) were estimated using a Cox proportional hazards model. Categorical data were compared using a stratifi ed Cochran -Mantel -Haenszel test. All statistical tests were two-sided. Results: Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688). Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratumadjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885). At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm). Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3 -4 hematologic toxic effects (requiring more supportive care) and more grade 3 -4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically signifi cant increase in febrile neutropenia (3.3% versus 3.1%; P = .80). Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm For the AGO-OVAR and GINECO and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm ( P = .166). Conclusions: The sequential addition of topotecan to carboplatin -paclitaxel did not result in superior overall response or progression-free or overall survival. Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer. [J Natl Cancer Inst 2006;98: 1036 -45 ]
Results of two large phase III trials published in the past decade ( 1 -3 ) showed that cisplatin -paclitaxel is superior to cisplatincyclophosphamide in patients with advanced ovarian cancer. Cisplatin -cyclophosphamide has therefore been adopted as the standard fi rst-line treatment for such patients. Subsequently, three prospective randomized trials have shown that carboplatin is at least as effective as, but less toxic than, cisplatin when used in combination with paclitaxel for treating advanced ovarian cancer ( 4 -6 ) . Therefore, the combination of carboplatin and paclitaxel has become the standard of care for patients with advanced ovarian cancer, as was recently confi rmed by the 2004 Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference ( 7 ) .
Despite this progress in treating ovarian cancer over the last several years, most ovarian cancer patients will experience a recurrence and eventually die from their disease ( 4 -6 ) . Thus, better fi rst-line chemotherapy for this disease is needed. One option is to add a third, non -cross-resistant drug to the standard carboplatin and paclitaxel treatment regimen. Several drugs that have been tried include anthracyclins (e.g., epirubicin or pegylated liposomal doxorubicin) and the nucleoside analog gemcitabine ( 8 -10 ) . Recently reported results of two phase III trials investigating carboplatin -paclitaxel with or without epirubicin have shown that the triplet combination had no statistically signifi cant advantage over carboplatinpaclitaxel in terms of response or progression-free or overall survival ( 8 , 9 ) . Other clinical trials of treatments for ovarian cancer have completed accrual ( 10 ) , but their results are not expected soon.
The topoisomerase I inhibitor topotecan is a another reasonable candidate to add to the standard carboplatin and paclitaxel treatment regimen because it displays some non -cross-resistance with paclitaxel ( 11 ) and it is as effective as either paclitaxel ( 12 , 13 ) or pegylated liposomal doxorubicin ( 14 , 15 ) in patients with recurrent ovarian cancer. The triplet combination of carboplatin, paclitaxel, and topotecan has been evaluated in two separate single-center phase II studies ( 16 , 17 ) . In these studies, carboplatin and paclitaxel were given together at standard doses and schedules and then followed by topotecan, which was well tolerated when given at a dosage of 1.25 mg/m 2 /day for 5 days, re peated every 21 days. The use of topotecan following carboplatin -paclitaxel has proven feasible with respect to toxicity, and the data from these two studies ( 16 , 17 ) showed that this triplet combination had a low rate of early relapse. Therefore, under the auspices of the Gynecologic Cancer Intergroup (GCIG), the German Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the French Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) performed a prospective randomized phase III study to compare the addition of topotecan to carboplatinpaclitaxel with carboplatin -paclitaxel in fi rst-line treatment of advanced epithelial ovarian cancer. This study was designed to incorporate topotecan as a third drug in a sequential setting in an attempt to avoid the toxicity expected if it were used in a simultaneous triple-drug regimen. Interim results as well as parts of this fi nal analysis were presented at the 2003 and 2005 annual meetings of the American Society of Clinical Oncology ( 18 , 19 ) .
P ATIENTS AND M ETHODS

Patients
This study was designed and performed in accordance with good clinical practice guidelines; German, Austrian, and French drug laws; relevant laws regarding the conduct of clinical studies; and the Declaration of Helsinki. German and Austrian centers of the AGO-OVAR and French centers of the GINECO participated in this study after obtaining approval from their respective local ethics committees. The trial was also certifi ed by the German Cancer Society and was registered in the clinical trials database of the U.S. National Institutes of Health (NCT00102375). All patients provided written informed consent before entry into the study.
Patients with histologically proven epithelial cancer of the ovary or fallopian tube or with extraovarian papillary serous carcinoma {International Federation of Gynecology and Obstetrics [FIGO] stage IIB -IV ( 20 ) } who had not previously undergone chemotherapy or radiotherapy were eligible for inclusion in this study. All tumors were graded according to the FIGO Grading System ( 21 ) . Patients had to be enrolled in the study within 6 weeks after undergoing debulking surgery and, at study entry, had to be at least 18 years old and to have adequate hematologic, renal, and hepatic function, defi ned as follows: absolute neutrophil count of at least 1.5 × 10 9 cells/L; platelet count of at least 100 × 10 9 cells/L; serum creatinine level of no more than 1.25 times the upper limit of normal (ULN); bilirubin level of no more than 1.5 times the ULN; and alkaline phosphatase level of no more than three times the ULN. Patients had to have an estimated glomerular fi ltration rate of at least 60 mL/minute and an Eastern Cooperative Oncology Group performance status ( 22 ) of 0, 1, or 2. Patients were excluded if they had nonepithelial or mixed epithelial ovarian tumors (e.g., carcinosarcoma) or ovarian tumors with low malignant potential (i.e., borderline tumors); had another malignancy; had previously undergone chemotherapy, immunotherapy, or radiotherapy for ovarian cancer; had severe neuropathy, cardiac arrhythmias, or congestive heart failure; or had received other chemotherapeutic drugs simultaneously or were scheduled to undergo endocrine therapy, simultaneous radiotherapy, or whole-abdominal radiotherapy during the study treatment period.
Patients were randomly assigned to one of the treatment arms and then stratifi ed according to residual tumor size and FIGO stage. Stratum 1 included patients who had FIGO stage IIB -III disease and a residual tumor size of less than or equal to 1 cm. Stratum 2 included patients who had FIGO stage IIB -III disease with a residual tumor size of more than 1 cm or who had FIGO stage IV disease.
Regular monitoring of the participating centers was performed by trained fi eld monitors who checked all data collected on case report forms against each patient's medical records as well as against reviews of the surgeon's and pathologist's reports (i.e., 100% monitoring). Quality-assurance measures consisted of extensive plausibility checks.
Treatment Regimens
Patients were randomly assigned to receive paclitaxel and carboplatin (TC arm) or paclitaxel and carboplatin followed by topotecan (TC-Top arm). In both arms, patients received six cycles of paclitaxel (175 mg/m 2 per cycle, administered intravenously over 3 hours) and carboplatin (area under the curve [AUC] of 5 mg • mL − 1 • min − 1 per cycle, administered intravenously over 30 -60 minutes) . Chemotherapy cycles had a length of 21 days. All patients could receive up to four additional cycles of carboplatin -paclitaxel if recommended by the physician. However, for patients in the TC-Top arm, these additional cycles had to be given before topotecan was administered. Patients in the TC-Top arm received four cycles of topotecan (1.25 mg/m 2 administered intravenously over 30 minutes on each of days 1 -5 of the cycle) after they had completed all their carboplatin -paclitaxel cycles. Again, the length of the cycles was 21 days. The carboplatin dose was calculated according to the method of Calvert et al. ( 23 ) , and the glomerular fi ltration rate was estimated according to the formula described by Jelliffe ( 24 ) . The maximal absolute dose given to each patient was limited to 385 mg for paclitaxel, 800 mg for carboplatin, and 2.7 mg/day for topotecan.
Dose reductions were allowed depending on predefi ned levels of hematologic or nonhematologic toxic effects as follows: levels 1 and 2 toxic effects, carboplatin reduced to AUC = 4 mg • mL − 1 • min − 1 for level 1 or 2 toxicity; paclitaxel reduced to 150 mg/m 2 (for level 1 toxicity) or to 135 mg/m 2 (for level 2 toxicity); and topotecan reduced to 1 mg/m 2 (for level 1 toxicity) or to 0.75 mg/m 2 (for level 2 toxicity). Treatment cycles were delayed if the patient's absolute neutrophil count was less than 1.5 × 10 9 cells/L or the platelet count was less than 100 × 10 9 cells/L. Primary prophylaxis with the use of granulocyte colony-stimulating factor (G-CSF) was not recommended; however, supportive G-CSF treatment could be initiated at the discretion of the patient's physician if the patient's absolute neutrophil count recovery took longer than 36 days.
All patients received premedication in the form of one dose of dexamethasone (20 mg), clemastine (2 mg), and ranitidine (50 mg), which was administered intravenously immediately before the paclitaxel infusion; patients in the TC-Top arm also received one dose of dexamethasone (20 mg) , which was administered intravenously immediately before the topotecan infusion. Antiemetic prophylaxis for both study arms consisted of serotonin type 3 receptor antagonists and corticoids. In case of disease progression during therapy, patients went off protocol treatment.
Toxicity and Quality-of-Life Measures
Grading of adverse events and toxic effects was based on the National Cancer Institute (NCI) Common Toxicity Criteria (CTC; version 2.0) ( 25 , 26 ) . All observed toxic effects were recorded continuously; blood chemistry parameters were measured before each treatment cycle and hematologic parameters were measured weekly. Quality of life was measured according to the global health status/quality-of-life score of the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaires QLQ-C30 (version 3.0) and QLQ-OV28 [version 1.0; ( 27 -29 ) ]. Patients used these questionnaires to assess their health-related quality of life before the start of treatment, after every other treatment cycle, after the last treatment cycle, and at 3 and 6 months after the end of treatment. The answers were scored according to EORTC guidelines ( 30 ) . Imaging methods (i.e., ultrasound, x-ray, computed tomography, or magnetic resonance imaging) were used to measure tumors at the following time points: before patients went on study (baseline); during the study (if appropriate); in patients who had measurable or evaluable disease after cycle 6 of carboplatin -paclitaxel and in patients in the TC-Top arm after cycle 4 of topotecan; and/or at the end of treatment. The same tumor assessment method that was used for the baseline measurement was used for each subsequent evaluation. Tumor response was graded according to the defi nitions of the World Health Organization ( 31 ) . Second-look surgery was allowed but was explicitly not recommended. Patients were followed up every 3 months during the fi rst 2 years after the end of treatment and every 6 months until the fi fth year. Thereafter, follow-up visits were performed yearly until death or loss to follow-up.
Randomization
Within each stratum, randomization lists for each study center were prepared before the start of the trial by using permuted blocks of randomly varying size. Randomization was carried out by the offi ces of AGO-OVAR in Germany and GINECO in France on the basis of patient data that the participating study centers provided.
Statistical Analyses
The primary endpoint of this trial was overall survival. Secondary endpoints were progression-free survival, response rate, toxicity, and quality of life. The trial was designed to detect an 8% absolute increase in 3-year survival in the TC-Top group (i.e., survival improvement from 50% in the TC group to 58% in the TC-Top group) with 80% power at a 5% statistical signifi cance level (two-sided) using a stratifi ed log-rank test, which required at least 541 events. Overall survival was defi ned as the time from randomization to death from any cause; survivors were censored on the date they were last known to be alive. Progression-free survival was defi ned as the time from randomization to disease progression or death from any cause; patients who were still alive without progressive disease at the time of analysis were censored on the date of their last follow-up. Overall tumor response rate was defi ned as the number of patients who had a partial or complete response [as defi ned by the World Health Organization ( 31 ) ] divided by the number of patients for whom the response could be assessed. Toxicity was measured by examining the frequency of grade 1 -4 toxic effects, graded according to the NCI-CTC and evaluated using the worst CTC score over all courses within patients. Time-to-event data were analyzed using the Kaplan -Meier method, and the stratifi ed log-rank test was used to compare distributions between treatment groups. Hazard ratios (HRs) with 95% confi dence intervals (CIs) were estimated using a Cox proportional hazards model. The proportional hazards assumption was checked visually from the survival plots and log -log plots of survival. We also included an interaction term of therapy and time in the Cox model to test for violations of the proportional hazards assumption, but the interaction was not statistically signifi cant. We therefore concluded that the data conformed to the proportional hazards assumption. The stratifi ed Cochran -Mantel -Haenszel test was used to compare categorical data. All P values are two-sided. Effi cacy analyses were performed on all randomly assigned patients (i.e., on an intentionto-treat basis). Patients who received at least one treatment cycle were included in the safety analysis. Patients who completed at least one QLQ-C30 questionnaire were included in the qualityof-life analysis. All statistical analyses were performed using SAS statistical software (version 8.2; SAS Institute, Cary, NC).
R ESULTS
Patients
Between December 1999 and March 2002, 1388 patients were screened for study eligibility by the AGO-OVAR and GINECO study offi ces. Of the 1308 patients who were enrolled in the study, 762 patients fulfi lled the criteria for stratum 1 and 546 patients fulfi lled the criteria for stratum 2 ( Fig. 1 ). After giving written informed consent, 650 patients were randomly assigned to the TC arm and 658 patients were randomly assigned to the TC-Top arm. Data were available for 1287 patients (639 patients in the TC arm and 648 patients in the TC-Top arm) for the analysis of toxicity. A total of 292 patients (147 patients in the TC, 145 patients in the TC-Top arm) qualifi ed for the evaluation of response to treatment. The treatment arms were well balanced with respect to baseline patient characteristics ( Table 1 ) .
Treatment Compliance
A total of 9453 treatment cycles were administered, 3889 in the TC arm and 5564 in the TC-Top arm. A total of 1289 (99%) patients received at least one cycle of treatment. In both arms, nearly 90% of patients (87% of those in the TC arm and 86% of those in TC-Top arm) received at least six cycles of carboplatinpaclitaxel. Of the 516 patients who received at least one cycle of topotecan, 458 (89%) received four cycles, corresponding to 70% of all patients in the TC-Top arm.
Treatment delays of 7 days or longer occurred more often in the TC-Top arm (14.4% of cycles 1 -10 delayed) than in the TC arm (8.2% of cycles 1 -6 delayed) ( P <.001); the treatment delays in the TC-Top arm were due mainly to delays in topotecan treatment (25.9% of topotecan cycles, cycles 7 -10, delayed). Similarly, the frequency of dose reductions was higher in the TC-Top arm during treatment with topotecan (5.8% of topotecan courses, cycles 7 -10, compared with 1.9% of TC cycles in the TC arm, cycles 1 -6, and 3.5% in the TC-Top cycles 1 -10 [ P <.001]) . The mean doses of paclitaxel for the TC arm and the TC-Top arm were 170.4 mg/m 2 and 171.4 mg/m 2 , respectively; the mean carboplatin dose was AUC of 5 mg • mL − 1 • min − 1 per cycle in both arms. The mean daily dose of topotecan was 1.2 mg/ m 2 . These amounts correspond to mean dose intensities of 94.3% and 94.1% for paclitaxel and 94.9% and 95.0% for carboplatin in the TC arm and TC-Top arm, respectively. The mean dose intensity for topotecan was 90.0%.
Treatment-Induced Toxicity
There were no major differences between the study arms with respect to the proportion of patients with hematologic ( Table 2 ) or nonhematologic toxic effects over the fi rst six courses of treatment ( Table 3 ) . However, when we compared the two arms over the entire course of treatment (i.e., cycles 1 -6 in the TC arm and cycles 1 -10 in TC-Top arm), grade 3 or 4 hematologic toxic effects, including anemia, leukocytopenia, neutropenia, and thrombocytopenia, were statistically signifi cantly more frequent in the TC-Top arm than in the TC arm. Consequently, more patients treated with TC-Top than with TC received blood transfusions, antibiotics, and/or G-CSF. Over the entire course of treatment (i.e., cycles 1 -6 in the TC arm and cycles 1 -10 in TC-Top arm), there were more grade 3 or 4 infections in the TC-Top arm than in the TC arm (5.1% versus 2.7%; P = .034), but the frequency of febrile neutropenia did not differ between treatment arms (3.1% for TC versus 3.3% for TC-Top; P = .80).
Quality-of-Life Measures
We analyzed quality of life only with respect to the global health score because the use of topotecan following carboplatinpaclitaxel induced statistically signifi cantly more toxicity without adding benefi t regarding effi cacy. Among patients who qualifi ed for the quality-of-life analysis, there was no statistically significant difference in global health scores between the 573 patients who received TC and the 581 patients who received TC-Top, either during treatment or during follow up (data not shown).
Response to Treatment and Survival
The 359 patients (27.5%) who had measurable disease at study entry qualifi ed for evaluation of response to treatment. Of those, response to treatment could be assessed in 292 patients (22.3%) . A total of 112 (76.2%) of the 147 assessable patients in the TC arm had a complete or partial response, compared with 100 (69%) of the 145 assessable patients in the TC-Top arm ( Table 4 ). There was no statistically signifi cant difference between treatment arms in the proportion of patients who had a complete or partial response ( P = .166).
The median follow-up time for surviving patients in both groups was 42 months (range = 0 -61 months). A total of 77 patients (5.9%) were lost to follow-up, 44 of them before disease progression.
A total of 947 patients (72.4%) experienced disease progression or recurrence during treatment or follow-up. Median progression-free survival time was 18.5 months (95% CI = 16.8 to 19.9 months) in the TC arm and 18.2 months (95% CI = 16.6 to 20.7 months) in the TC-Top arm ( Fig. 2, A ) . The stratum-adjusted hazard ratio was 0.97 (95% CI = 0.85 to 1.10; stratifi ed log-rank P = .688). Among the patients in stratum 1, median progressionfree survival time was 28.6 months (95% CI = 24 to 33.2 months) in the TC arm and 26.4 months (95% CI = 22.5 to 30.1 months) in the TC-Top arm, corresponding to a hazard ratio of 1.02 (95% CI = 0.85 to 1.22; P = .844). Among the patients in stratum 2, † Stratum 1 = FIGO stages IIB -IIIC and residual tumor size less than or equal to 1 cm; Stratum 2 = FIGO stage IV or residual tumor size of greater than 1 cm. ‡ FIGO Grading System ( 21 ) . ( 25 , 26 ) ]. If patients received pRBCs, antibiotics, or G-CSF, this was coded as a toxicity of grade 3; if not, it was coded as grade 0. TC = paclitaxel -carboplatin treatment; TC-TOP = paclitaxel -carboplatin -topotecan treatment; pRBCs = packed red blood cells; G-CSF = granulocyte colony-stimulating factor.
† Two-sided P value for differences in the proportions of patients with grades 3 or 4 toxicity between TC cycles 1 -6 and TC-TOP cycles 1 -10 (stratifi ed Cochran -Mantel -Haenszel test). median progression-free survival time was 13.1 months in both arms (95% CI = 11.7 to 14.6 months for the TC arm and 12 to 14.8 months for the TC-Top arm), corresponding to a hazard ratio of 0.93 (95% CI = 0.78 to 1.12; P = .446).
A total of 625 patients (47.8%) died while undergoing treatment or during follow-up ( Fig. 2, B ) . Median overall survival time was 44.5 months (95% CI = 39.0 to 51.5 months) in the TC arm and 43.1 months (95% CI = 37.6 to 48.7 months) in the TC-Top arm. The stratum-adjusted hazard ratio was 1.01 (95% CI = 0.86 to 1.18; stratifi ed log-rank P = .885). The estimated 3-year survival rates were 57.1% (95% CI = 54.3% to 59.9%) for both arms, 58.5% (95% CI = 54.4% to 62.3%) for the TC arm, and 55.7% (95% CI = 51.6% to 59.5%) for the TC-Top arm. The overall survival curves by treatment group within strata 1 and 2 are shown in Figs. 3, A and 3 , B , respectively. In stratum 1, median overall survival time was 56.5 months (95% CI = 54.1 months to ∞ ) for the TC arm, whereas in the TC-Top arm, the median survival time had not yet been reached at the time of this analysis. However, the lower limit of the 95% confi dence interval was 52.6 months. The corresponding hazard ratio was 1.08 (95% CI = 0.85 to 1.38; P = .512). The estimated 3-year survival rates were 70.7% (95% CI = 65.6% to 75.2%) for the TC arm and 66.3% (95% CI = 61.1% to 71.1%) for the TC-Top arm. In stratum 2, median overall survival time was 28.6 months (95% CI = 24.7 to 32.6 months) for the TC arm and 27.2 months (95% CI = 23.9 to 33.7 months) for the TC-Top arm, corresponding to a hazard ratio of 0.96 (95% CI = 0.78 to 1.18; P = .706). The estimated 3-year survival rates were 41.3% (95% CI = 35.2% to * Data refl ect the number of patients who had at least one occurrence of the indicated grade 3 or 4 toxicity according to the National Cancer Institute Common Toxicity Criteria [version 2 ( 25 , 26 ) ]. TC = paclitaxel -carboplatin treatment; TC-TOP = paclitaxel -carboplatin -topotecan treatment.
† Two-sided P value for differences in the proportions of patients with grades 3 or 4 toxicity between TC cycles 1 -6 and TC-TOP cycles 1 -10 (stratifi ed Cochran -Mantel -Haenszel test).
‡ The proportion of patients with grade 2 alopecia is reported. § As determined by increased serum creatinine levels. * TC = paclitaxel -carboplatin treatment; TC-TOP = paclitaxel -carboplatin -topotecan treatment; n = number; CI = confi dence interval. † Two-sided P values for differences in the proportions of patients with overall response (complete or partial response) between treatment arms: P = .1663 (chi-square test), P = .1901 (Fisher's exact test), and P = .1487 (stratifi ed Cochran -Mantel -Haenszel test). 47.3%) for the TC arm and 41.1% (95% CI = 35.1% to 47.0%) for the TC-Top arm.
Because only 70% of the patients who were randomly assigned to the TC-Top arm completed four cycles of topotecan, we performed a per-protocol analysis of survival among patients who completed at least six cycles of carboplatin -paclitaxel and had no progression of disease within 3 weeks after the sixth cycle of carboplatin -paclitaxel (555 patients in the TC arm and 558 patients in the TC-Top arm). Also, patients in the TC-Top arm had to have received at least one cycle of topotecan (507 patients in the TC-Top arm). The stratum-adjusted hazard ratio was 1.01 (95% CI = 0.84 to 1.21; stratifi ed log-rank P = .884), which is in line with the results of the intention-to-treat analysis.
Treatment for recurrence was similar in the two study arms: Approximately 29% of patients with recurrences in each arm were treated with pegylated liposomal doxorubicin, 25% with platinum-based combination therapy, 14% with platinum monotherapy, 10% with alkylating agents, and 7% with gemcitabine. Only 9% were treated with topotecan (14% in the TC arm versus 4% in the TC -Top arm).
D ISCUSSION
Despite the implementation of carboplatin and paclitaxel as the standard of care in fi rst-line treatment of ovarian cancer, rates of recurrence and death remain high. Thus, better treatments for this disease are needed. One option is to add a third, noncross-resistant drug to carboplatin and paclitaxel, as we have done in this study. Specifi cally, we tested whether sequential administration of topotecan would improve the effi cacy (i.e., overall survival, overall response, and progression-free survival) of carboplatin and paclitaxel. We found that it did not. We also found that the sequential addition of topotecan to carboplatinpaclitaxel induced higher rates of hematologic toxic effects and infections, requiring statistically signifi cantly more supportive care ( Table 2 ). This higher toxicity is consistent with the results of earlier phase II studies ( 16 , 17 ) . The clinical consequences of the higher toxicity rates in the TC-Top arm were acceptable. For example, the rate of grade 3 or 4 febrile neutropenia in the TC-Top arm was not statistically signifi cantly different from the rate in the TC arm (3.3% versus 3.1%) and, although the rate of grade 3 or 4 infection was statistically signifi cantly higher in the TC-Top arm than in the TC arm (5.1% versus 2.7%), the levels in both arms were acceptable. Also, global quality-of-life scores were not worse in those treated with topotecan.
Even if sequential topotecan had improved survival after carboplatin -paclitaxel, the resulting hazard ratio reduction would probably have been less than 14% (equivalent to the lower 95% confi dence limit of the estimated hazard ratio of 0.86). There are several possible reasons why we observed no improvement in 
A B
survival among the TC-Top arm. First, this lack of improvement could be due to patients in the TC arm receiving treatment with topotecan, maybe without having progressed. This possibility is unlikely because only 26 (2%) of the enrolled patients were treated without evidence of disease progression. Furthermore, only a few patients (9%) were treated with topotecan after progression, although there was a difference of 10% (TC-arm, 14%; versus TC-Top arm, 4%) between treatment arms. Postrecurrence therapy is known to have an impact on overall survival; nevertheless, it is not now possible to standardize postrecurrence/ pro gression therapy ( 32 , 33 ) . Also, these different percentages of topotecan use might be of minor relevance because the median progression-free and overall survival times reported here are in the same range of results achieved with carboplatin -paclitaxel in other studies ( 4 , 6 ) . Another limitation of this study might be that 19 patients (1.5%) never started treatment and 157 patients (12%) stopped treatment earlier than intended, mainly because of progressive disease. It can be argued that a shorter treatment period and a lower total dose of carboplatin -paclitaxel might have resulted in shorter survival. Furthermore, it is possible that patients who progressed under carboplatin -paclitaxel treatment and thus went off treatment might have profi ted from topotecan treatment. However, we repeated the analysis on a per-protocol basis and obtained results that agreed with those obtained in the intention-to-treat analysis. Moreover, we took this dropout rate into consideration when calculating the sample size. According to the Third International Ovarian Cancer Consensus Conference, the standard arm of our trial was appropriate in terms of drugs and dosages ( 33 ) . Our results are in agreement with those of the MITO-1 study, which used topotecan as consolidation treatment for ovarian cancer after carboplatin -paclitaxel ( 34 ) . However, there were major differences between these studies. For example, we used a tripledrug regimen in a sequential way (i.e., up-front randomization), whereas the MITO-1 study was a consolidation study (i.e., randomization after response to six cycles of carboplatin -paclitaxel). The two studies used different dosages of topotecan: 1.25 mg/m 2 on cycle days 1 -5 (our study) versus 1.5 mg/m 2 on cycle days 1 -5 (MITO-1 study) -as well as different primary endpointsoverall survival (our study) versus progression-free survival (MITO-1 study). Despite these differences, topotecan did not improve the effi cacy of six cycles carboplatin -paclitaxel in either setting. This is the fi rst and, to our knowledge, only phase III study to investigate topotecan in a sequential triple-drug regimen for fi rstline therapy of advanced ovarian cancer. Interpretation of the negative results of this trial should be limited to the sequential use of topotecan. Other investigators have applied a doublet combination approach by adding topotecan to platinum for four cycles followed by four cycles of platinum -paclitaxel ( 10 , 35 ) . This approach may result in superior effi cacy, considering that preclinical models have suggested an advantage for the combination of topotecan and platinum due to the inhibition of DNA synthetic pathways involved in the repair of platinum -DNA adducts ( 36 ) . Because increased toxicity makes it unfeasible to treat patients with a simultaneous drug regimen of carboplatin, paclitaxel, and topotecan, the above-mentioned sequential doublet approach might be superior to the sequential single agent used in this study. Results of these two other prospective randomized phase III studies may help our understanding of the role of topotecan as part of fi rst-line therapy of advanced ovarian cancer.
Both studies have recently completed accrual and results are expected within the next few years. In the meantime, in accordance with the results of the 2004 consensus statement on the management of ovarian cancer of the Third International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference ( 7 ) , carboplatin -paclitaxel remains the standard of care for patients with advanced ovarian cancer.
